Howard Johnson is the Vice President, Corporate Development at Lion Biotechnologies, an oncology company developing immunotherapies based on patient-specific T-cells. Entrepreneurial executive with thirty-years of experience in operations, finance, business development, and investor relations at biotechnology companies. A founding investor and initial Board Member of Acorda Therapeutics.